OBJECTIVES: Chronic thromboembolic pulmonary hypertension is a fatal disease if left untreated, and pulmonary endarterectomy (PEA) is the potentially curable treatment of choice. We aimed to estimate the current in-hospital mortality rate, complication rate and longterm survival for patients with chronic thromboembolic pulmonary hypertension undergoing PEA in Denmark.
INTRODUCTION
Chronic thromboembolic pulmonary hypertension (CTEPH) is a progressive and debilitating disease with a poor prognosis if left untreated. The incidence is approximately 5 cases per million per year but might be under-reported due to vague symptoms, misdiagnosis and referral bias [1, 2] . The pathogenesis is thought to be recurrent venous thromboembolism and/or incomplete thrombi resolution [3] . This theory is supported by prospective registry data showing that 80% of patients with CTEPH have a prior history of venous thromboembolism [4, 5] . Likewise, up to 9% of patients with an acute pulmonary embolism may develop symptomatic CTEPH within 2 years from first admission [6] [7] [8] .
The mechanical obstruction of the pulmonary arteries cause an increase in pulmonary vascular resistance (PVR) and pulmonary arterial pressure (PAP) with a subsequent increased right ventricular afterload and ventricular failure [3, 4, 9] . A secondary distal vasculopathy, resembling that seen in idiopathic pulmonary arterial hypertension, may develop over time and contribute to the haemodynamic and symptomatic decline [10, 11] .
The natural course of CTEPH is related to a poor prognosis. A 3-year mortality of 90% in patients with mean PAP > _50 mmHg has been reported in a historical cohort [12] . However, the disease is potentially curable with pulmonary endarterectomy (PEA) [9] . The technique was introduced in the 1970s [13, 14] and has markedly improved the outcome of CTEPH since. Surgery is the treatment of choice in both the ESC/ERS and the AHA guidelines on CTEPH [9, 15, 16] . Current in-hospital mortality after PEA is reported to be between 2% and 5% in experienced centres [5, 17] and the 5-year survival rate is between 76% and 86% [17] [18] [19] .
A recent prospective European/Canadian registry reported 3-year survival of 89% after PEA, while inoperable patients receiving medical therapy had a 70% survival after 3 years [20] . The introduction of targeted therapy with the soluble guanylate cyclase stimulator riociguat and percutaneous balloon pulmonary angioplasty has shown promising results but remain confined to patients technically inoperable or with residual pulmonary hypertension (PH) after PEA [15, 21, 22] .
In 2005, we reported the first 50 cases of PEA performed in Denmark between 1994 and 2004 [23] . Overall in-hospital mortality was 24%, with a steep learning curve, proved by a marked fall in in-hospital mortality after 2000 [23] . Today, with more than 20 years of experience with a national PEA programme at our institution, and more than 200 performed procedures, we report the current in-hospital mortality, complication rate and long-term survival for patients with CTEPH undergoing PEA in Denmark.
METHODS

Study population
This is a single-centre retrospective cohort study of patients with CTEPH undergoing PEA at Aarhus University Hospital, Denmark, from 1994 until September 2016. Our institution is the only centre in Denmark performing PEA (The Danish National Center for PEA; 5.7 million inhabitants). Patients with suspected CTEPH are referred for a diagnostic workup and consideration for PEA surgery. A number of patients from neighbouring countriesSweden and Iceland-have been referred as well.
Baseline diagnostic workup with right heart catheterization, ventilation/perfusion scan, computed tomography and digital subtraction angiography was performed before operability was assessed. A 6-min walking test (6MWT) was additionally performed after the Year 2000. A multidisciplinary heart team consisting of surgeons, cardiologists, radiologists and anaesthesiologists with expertise in CTEPH and PEA made the decision of operability. All patients were anticoagulated with warfarin (international normalized ratio 2-3) for at least 3 months prior to diagnosis and indefinitely if CTEPH was present.
Surgery
In general, implantation of a percutaneous vena cava filter was performed prior to surgery. The filters were considered permanent and hence not removed once implanted. PEA procedures were performed according to the principles described in detail by Jamieson et al. [13, 14, 17] . The technical approach was similar throughout the study period and was as described previously [23] . Throughout the study period, 3 surgeons were responsible for the PEA operations. Since 2002, the same 2 surgeons have carried out all PEA operations in collaboration.
Postoperative care and follow-up
Postoperative care was handled at the intensive care unit. Here, patients were monitored at least 24 h postoperatively with invasive haemodynamics using a pulmonary artery catheter with continuous cardiac output measurements. Invasive haemodynamics were obtained at diagnosis, immediately presurgery, 1 h, 6 h and 24 h postoperative in all patients.
Clinical follow-up was conducted at our institution 3 months after surgery with echocardiography and 6MWT. Hereafter, follow-up was on clinical indication or performed through systematic review of patient files, and through a search in the Danish Civil Registration System [24] as well as the Danish National Patient Registry [25] . Patients from foreign countries were followed up at PH centres in their home country.
Outcome variables and definitions
Primary outcome was all-cause mortality. Survival rate was estimated from the date of surgery until death, last known status or end of study. Perioperative complications served as secondary outcome variables. Persistent PH was defined as PVR >500 dynes s cm -5 measured on Day 1 postoperatively. This limit has previously been demonstrated to be an important predictor for postoperative mortality [17] . Complete PEA was defined as a bilateral dissection into the subsegmental branches.
At the end of the study on 15 September 2016, vital status was obtained for all Danish patients through a search in the Danish Civil Registration System [24] . According to the time of PEA surgery, the cohort was divided into an early and late cohort. 
Statistics
Continuous variables were reported as mean with standard deviation or as median with interquartile range (IQR). Categorical variables were reported as absolute frequencies and percentages. Kaplan-Meier (KM) curves were generated with time from surgery as time scale and all-cause mortality as outcome. Patients lost to follow-up were censored at the time of their last visit or last known status. Otherwise, patients were censored at the end of study.
When comparing continuous variables, a 2-sample t-test or paired t-test was used when appropriate. Wilcoxon 2-sample test or Wilcoxon signed-rank test was used when normal distribution could not be assumed. Fisher's exact test was used for categorical variables. A P-value (2 sided) <0.05 was considered statistically significant. STATA software (STATA IC 14.1 for Mac) was used for statistical analysis.
The study was approved and compliant to the requirements stated by the Danish Data Protection Agency (ID 1-16-02-171-13) and the Danish Health and Medicines Authorities (ID 3-3013-343/1). According to Danish law, ethical committee approval and informed consent were not required to conduct the present study.
RESULTS
A total of 239 consecutive patients with CTEPH were operated in the study period. Of those, 53 patients underwent PEA in the early decade (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) , and 186 patients underwent PEA in the late decade (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) . Mean age of the total cohort was 60 years, with an even distribution of gender. A history of venous thromboembolism was present in 70% of patients, and a coagulation abnormality was found in 15% of cases. Of these, lupus anticoagulant and Factor V Leiden mutation were present in 50%. Coagulation status was unknown in 37 patients.
The majority of patients were in World Health Organization (WHO) functional Class III upon operation. Further baseline characteristics are summarized in Table 1 . No significant difference was observed in the baseline haemodynamic profile or 6MWT between the early and late cohort. However, significantly more patients were in WHO functional Class IV in the early cohort.
Surgery
An inferior vena cava filter was implanted percutaneously in 94% prior to PEA. The median circulatory arrest time was 38 min (IQR: 29-47) and the endarterectomy was surgically categorized as complete in 82% of cases. In 10% of patients, the operation was combined with other cardiac interventions. Coronary artery bypass surgery was most common (n = 12), followed by atrial septal defect closure (n = 4), aortic valve prosthesis (n = 3), tricuspid ring annuloplasty (n = 2), cryoablation for atrial fibrillation (n = 2) and ascending aortic replacement (n = 1).
The 2 cohorts differed significantly on circulatory arrest time, with a shorter arrest time in the late cohort (Table 2) . However, the surgical result, in terms of being a complete endarterectomy, did not differ significantly between cohorts.
Perioperative complications and mortality
The median time at the intensive care unit was 4 days (IQR: 3-7), with no significant difference between the cohorts [5 (IQR 3-8) vs 4 (IQR 3-7) days, P = 0.17]. In 42% of patients, a perioperative complication occurred. Most common was persistent PH ( Table 2 ). The rate of irreversible neurological complications was significantly lower in the late cohort. Of the 4 patients with neurologic damage, 2 had mild cognitive impairment persisting at 12-month follow-up (were able to maintain work), 1 had dysfunction of the lower left extremity and 1 died due to anoxic brain damage perioperative. None of the events were related to combined procedures. However, arrest time was prolonged in 3 of the 4 with neurological damage (arrest time; 81, 29, 64 and 54 min, respectively). In-hospital, another 9 patients experienced reversible neurologic symptoms, with full remission before discharge. These were extrapyramidal symptoms (n = 7), diplopia (n = 1) and unilateral paralysis (n = 1). The use of extracorporeal membrane oxygenation also reached significance, reflecting a higher rate of persistent PH in the early cohort. Of the 9 patients receiving extracorporeal membrane oxygenation therapy, 1 patient in the early cohort and 2 patients in the late cohort survived. Table 2 summarizes the perioperative complication rates.
A total of 20 patients died in-hospital. The in-hospital mortality rate was significantly higher in the early cohort ( Table 2 ). The causes of in-hospital death was categorized as persistent PH (9 of 20 cases), bleeding (7 of 20), sepsis (3 of 20) and anoxic brain damage (1 of 20) . The in-hospital mortality rate improved markedly over the years, and during the last 5 years, 80 patients were operated with an in-hospital mortality rate of 2.5%.
Haemodynamic changes
Noticeable haemodynamic improvements were observed during the first 24 h postoperative period. Mean PAP, cardiac index and PVR significantly improved as early as 1 h after operation, with a clear further improvement in mean PAP during the next 24 h. Likewise, cardiac index increased significantly during the first postoperative day. Table 3 summarizes the haemodynamic changes during the first perioperative day. 
Follow-up and survival
Median follow-up time was 4.4 years (IQR: 0.5-7.9), and at the end of the study, 69 patients were dead, 1 was lost to follow-up due to emigration 4 years after PEA and 32 patients were foreign citizens without follow-up data available. Three-month clinical follow-up data were present in 184 of 219 (84%) patients surviving until discharge. Of these 184 patients, 84% were in WHO functional Class I/ II. Their 6MWT was significantly improved from baseline (348 ± 129 m) to a mean of 448 ± 104 m (P < 0.001). At 12 months, 136 patients had follow-up at our institution and still 81% of these were in WHO functional Class I/II. The 6MWT was 428 ± 123 min and was not significantly different from 3 months (P = 0.33).
The KM-estimated 3-, 5-and 10-year survival rates for the total cohort were 84% [95% confidence interval (CI): 77.8-88)], 77% (CI: 70.7-82.7) and 62% (CI: 53-69.1), respectively. The KM survival curve is illustrated in Fig. 1 , while KM survival curves for the 2 cohorts are displayed in Fig. 2 . The 5-year survival rate for the early cohort was 68% (CI: 53.4-78.6) and for the late cohort 80% (CI: 72.5-86.2).
Conditional 5-and 10-year KM estimated survival for patients surviving 30 days after PEA was 85% (CI: 78.7-89.9) and 68% (CI: 58.7-75.4), respectively. In the early cohort, conditional 5-year survival was 87% (CI: 72.8-94.7), and in the late cohort, it was 84% (CI: 76.5-89.8). In patients with persistent PH after surgery conditional 5-year survival was 76% (CI: 54.7-88.6), and in patients without persistent PH it was 87% (CI: 80.4-91.8).
DISCUSSION
This study documents the advances in surgical management and outcome of patients with CTEPH undergoing PEA in Denmark. One of the main findings is a low perioperative mortality rate of 2.5% during the last 5 years. This is comparable to high-volume centres [5, 17] . The annual number of operated patients has also increased significantly during the study period. This may be both a cause and a consequence to the improved surgical outcome and decreased in-hospital mortality risk. In addition, the improving outcome may likely explain the tendency to operate less symptomatic patients with higher age in the latest cohort.
However, perioperative complications were still frequent and occurred in nearly half of the patients. Similar results have been reported by the European/Canadian registry [5] . Persistent PH was present in 18% of our cohort after PEA. The relevance of persistent PH on outcome was highlighted by the fact that half of the in-hospital deaths were attributed to this complication. The rate of irreversible neurologic damage differed significantly between the 2 cohorts. This is likely explained by the shorter arrest time used in the late cohort, which is correlated to the neurologic outcome [5] . Importantly, although the general perioperative complication rates were not significantly different between the 2 cohorts, the in-hospital mortality rate was significantly lower in the late cohort.
Baseline PVR and 6MWT, along with persistent PH (and postoperative PVR) has been identified as predictors of perioperative death [5, 17] . We found that the frequency of persistent PH was borderline lower in the late cohort, which-taken together with a significantly lower postoperative PVR and mean PAP-signifies a better haemodynamic outcome in the late cohort. Prior to surgery, the patients in the late cohort were older; fewer were in WHO functional Class IV or on continuous oxygen therapy upon referral. On the other hand, 24% of patients in the late cohort were receiving PDE5 inhibitors at baseline. Studies have concluded that PHspecific treatment prior to PEA delays referral for surgery [17, 26, 27] , has no benefit [26] and may even be associated with an increased risk of perioperative death [20] . Madani et al. reported similar improvements in in-hospital mortality despite persistent PH after surgery. In patients with persistent PH, those operated in the latest 500 cases had significantly reduced in-hospital mortality rates [17] . Similarly as Madani et al. reported, the reduced inhospital mortality in our latest cohort may be a result of improved surgical outcome and better perioperative management. The increased access to pharmacological therapies targeted persistent PH could contribute to the improved in-hospital outcome in the latest cohort [17] .
Long-term survival after pulmonary endarterectomy
Significant improvements in symptoms, haemodynamic profile and 6MWT were observed after PEA. The improvements in symptoms and exercise capacity seen at 3 months follow-up persisted 1 year after PEA. Similar results have been reported previously [28] . Long-term survival in our cohort was markedly improved, when comparing with the historic data on untreated patients [12] . The current 3-and 5-year survival rates in our latest cohort are in line with the survival rates reported from large volume centres in the USA and Europe [17, 18, 20, 29, 30] . Few studies have reported 10-year survival estimates, but data from the 2 largest PEA centres have shown a 10-year survival rate of 72-75% [17, 30] . Our 10-year survival rate of 62% is lower. However, the difference is influenced by older age of our patients and by a high perioperative mortality rate in the early cohort.
When comparing the early and late cohort, the difference observed in Fig. 2 is driven by the significantly higher in-hospital mortality rate in the early cohort. However, conditional longterm survival was equally good in the 2 cohorts.
CONCLUSION
In conclusion, PEA is a very effective treatment for patients with CTEPH and should be considered in all patients. It significantly improves haemodynamics, exercise capacity and long-term survival for the patients. With an in-hospital mortality rate of 2.5% and a 5-year survival rate of 80%, the results of the PEA programme in Denmark is comparable to high-volume international centres. 
